Single-source·Sep 1, 2026·1 sources analyzed
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused (endpoints)
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused (endpoints)